Tadalafil Tablet, Film Coated
Product Images NDC 71610-581

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71610-581). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 10 mg (71610 0581 04)

Bottle Label 10 mg (71610 0581 04)
This is a description of a medication called Tadalafil, USP, which is available in the form of tablets. A single pack contains four tablets, with each tablet having a strength of 10mg. The National Drug Code (NDC) for this product is 71610-0581-04. The storage recommendation for this product is to keep it at a controlled room temperature between 68-77 degrees Fahrenheit (20-25 degrees Celsius), and away from children. The expiration date for this product is December 2024.*
FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

10 (Tadalafil Tablets Usp 1)

FDA Label Image

10 (Tadalafil Tablets Usp 2)

10 (Tadalafil Tablets Usp 2)
This appears to be a table showing the difference in blood pressure (measured in mmHg) between patients taking Tadalafil and those taking a placebo. The table includes measurements for standing systolic and diastolic blood pressure, as well as supine systolic and diastolic blood pressure. The table also includes a column for time in hours. There is some unclear text and symbols, so the full context and interpretation of the data is not available without further clarification or context.*
FDA Label Image

10 (Tadalafil Tablets Usp 3)

10 (Tadalafil Tablets Usp 3)
This appears to be a table showing the standing and supine systolic blood pressure readings (in mmHg) for two different conditions, possibly related to a medical study involving Tadalafil 20 mg and doxazosin 8 mg versus a placebo and doxazosin 8 mg. However, the text "aohowo" and "Aohowd" do not seem to be relevant information, and the row of numbers with dashes may be indicating a timeline.*
FDA Label Image

10 (Tadalafil Tablets Usp 4)

10 (Tadalafil Tablets Usp 4)
This appears to be a document tracking the effects of different medications on systolic blood pressure over time. The medications being tested include 20mg of tadalafil and 8mg of doxazosin, administered at 8:00am, as well as a placebo. The document includes a graph showing the changes in systolic blood pressure over time after the administration of these medications, but the graph itself is not included in the text.*
FDA Label Image

10 (Tadalafil Tablets Usp 5)

10 (Tadalafil Tablets Usp 5)
This is a chart showing the plasma concentration of Tadalafil in mcg/L over time after taking different doses. A single 20-mg dose and a single 5-mg dose were compared to a once-daily 5-mg dose for five days. The plasma concentration increased over time and reached a peak at around 4-6 hours after taking the medication. The data is measured up to 120 hours (5 days) after administration.*
FDA Label Image

10 (Tadalafil Tablets Usp 6)

10 (Tadalafil Tablets Usp 6)
This text is a graph and not enough information is provided to generate a useful description.*
FDA Label Image

10 (Tadalafil Tablets Usp 7)

10 (Tadalafil Tablets Usp 7)
This is a comparison study between Tadalafil 5 mg and placebo, where the efficacy of Tadalafil is evaluated based on the change from baseline in IPSS total score. The treatment duration is not available. The asterisk after the treatment names indicates a statistically significant difference between the two treatments.*
FDA Label Image

10 (Tadalafil Tablets Usp 8)

FDA Label Image

10 (Tadalafil Tablets Usp 9)

10 (Tadalafil Tablets Usp 9)
This text appears to be presenting some results of a study or experiment. Tadalafil (5 mg) and Placebo were likely compared, and some measure of effectiveness was assessed based on the IPSS Total Score. The notation "p<0.01" likely indicates a significant difference between the two groups. The duration of treatment in weeks was also recorded. However, without further context, it is difficult to provide more information or draw any conclusions beyond this.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.